Effect of tamoxifen and retinoic acid on bradykinin induced proliferation in MCF-7 cells

Journal of Cellular Biochemistry

Volumn 106, Issue 3, 2009, Pages 473-481

  Searovic, Paola ^a   Alonso, Marcelo ^a   Oses, Carolina ^a   Pereira Flores, Karla ^a   Velarde, Victoria ^a   Saez, Claudia G ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

BRADYKININ; BREAST CANCER; CHEMOPREVENTION; RETINOIC ACID; TAMOXIFEN

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROTEIN BCL 2; RETINOIC ACID; TAMOXIFEN; UVOMORULIN; CADHERIN; MYC PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BRADYKININ; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, BRADYKININ B2; SIGNAL TRANSDUCTION; TAMOXIFEN; TRETINOIN;

EID: 62649099328     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22031     Document Type: Article

References (40)

1. Bachvarov DR, Houle S, Bachvarova M, Bouthillier J, Adam A, Marceau F. 2001. Bradykinin B(2) receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. J Pharmacol Exp Ther 297:19-26.
2. Balkwill F, Mantovani A. 2001. Inflammation and cancer: Back to Virchow? Lancet 357:539-545.
3. Barki-Harrington L, Daaka Y. 2001. Kinin-regulated growth of androgen insensitive prostate cancer PC3 cells requires direct interaction between bradykinin 1 and bradykinin 2 receptors. J Urol 165:2121-2125.
4. Benkoussa M, Brand C, Delmotte MH, Formstecher P, Lefebvre P. 2002. Retinoic acid receptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter. Mol Cell Biol 22:4522-4534.
5. Blaukat A, Alla SA, Lohse MJ, Müller-Esterl W. 1996. Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. Biol Chem 271:32366-32374.
6. Chen YP, Chao J, Chao L. 1988. Molecular cloning and characterization of two rat renal kallikrein genes. Biochemistry 27:7189-7196.
7. Costa-Neto CM, Dillenburg-Pilla P, Heinrich TA, Parreiras-e-Silva LT, Pereira MQ, Reis RI, Souza PP. 2008. Participation of kallikrein- kinin system in different pathologies. Int Immunopharmacol 8:135-142.
8. Deming SL, Nass SJ, Dickson RB, Trock BJ. 2000. C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83:1688-1695.
9. Drube S, Liebmann C. 2000. In various tumor cell lines the peptide bradykinin B(2) receptor antagonist Hoe 140 (Icatibant), may act as mitogenic agonist. Br J Pharmacol 131:1553-1560.
10. el-Dahr SS, Figueroa CD, Gonzalez CB, Muller-Esterl W. 1997. Ontogeny of bradykinin B2 receptors in the rat kidney: Implications for segmental nephron maturation. Kidney Int 51:739-749.
11. Fanidi A, Harrington EA, Evan Gl. 1992. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554-556.
12. González-Mariscal L, Lechuga S, Garay E. 2007. Role of tight junctions in cell proliferation and cancer. Prog Histochem Cytochem 42:1-57.
13. Greco S, Muscella A, Elia MG, Romano S, Storelli C, Marsigliante S. 2004. Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cell Physiol 201:84-96.
14. Greco S, Elia MG, Muscella A, Romano S, Storelli C, Marsigliante S. 2005. Bradykinin stimulates cell proliferation through an extracellular-regulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture. J Endocrinol 186:291-301.
15. Greco S, Storelli C, Marsigliante S. 2006. Protein kinase C (PKC)-delta/-epsilon mediates the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. J Endocrinol 188:79-89.
16. Jacobs HS. 2000. Hormone replacement therapy and breast cancer. Endocr Relat Cancer 7:53-61.
17. Kang Y, Cortina R, Perry RR. 1996. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells. J Natl Cancer Inst 88: 279-284.
18. Lei BL, Guo ZG. 1998. Bradykinin B2 receptor antagonist icatibant reduces inhibitory effect of captopril on growth of cultured neonatal rat cardiomyocytes. Zhongguo Yao Li Xue Bao 19:241-244.
19. Ma JX, Wang DZ, Ward DC, Chen L, Dessai T, Chao J, Chao L. 1994. Structure and chromosomal localisation of gene (BDKRB2) encoding the bradykinin B2 receptor. Genomics 23:362-369.
20. Maeda H, Wu J, Okamoto T, Maruo K, Akaike T. 1999. Kallikrein kinin in infection and cancer. Immunopharmacology 43:115-128.
21. McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, Fujisaki J, Aldrich RW, Jarnagin K. 1991. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci 88:7724-7728.
22. Michineau S, Muller L, Pizard A, Alhenc-Gelas F, Rajerison RM. 2004. N-linked glycosylation of the human bradykinin B2 receptor is required for optimal cell-surface expression and coupling. Biol Chem 385:49-57.
23. Nass SJ, Dickson RB. 1997. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44:1-22.
24. Park S, Kim B, Kim J, Won KJ, Lee S, Kwon S, Cho S. 2003. Tamoxifen induces vasorelaxation via inhibition of mitogen-activated protein kinase in rat aortic smooth muscle. J Vet Med Sci 65:1155-1160.
25. Pesquero JB, Bader M. 1998. Molecular biology of the kallikrein-kinin system: From structure to function. Braz J Med Biol Res 31:1197-1203.
26. Piché A, Grim J, Rancourt C, Gómez-Navarro J, Reed JC, Curiel DT. 1998. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 58:2134-2140.
27. Pizard A, Blaukat A, Michineau S, Dikic I, Müller-Esterl W, Alhenc-Gelas F, Rajerison RM. 2001. Palmitoylation of the human bradykinin B2 receptor influences ligand efficacy. Biochemistry 40:15743-15751.
28. Reed JC. 1994. Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6.
29. Regoli D, Barabé J. 1980. Pharmacology of bradykinin and related peptides. Pharmacol Rev 32:1-46.
30. Robert RM, Gulick WJ. 1989. Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis by expression of mutant ras oncogene. J Cell Sci 94:527-535.
31. Saez CG, Velásquez L, Montoya M, Eugenín E, Alvarez MG. 2003. Increased gap junctional intercellular communication is directly related to the anti-tumor effect of all-trans-retinoic acid plus tamoxifen in a human mammary cancer cell line. J Cell Biochem 89:450-461.
32. Simstein R, Burow M, Parker A, Weldon C, Beckman B. 2003. Apoptosis, chemoresistance, and breast cancer: Insights from the MCF-7 cell model system. Exp Biol Med 228:995-1003.
33. Stewart JM. 2003. Bradykinin antagonists as anti-cancer agents. Curr Pharm Des 9:2036-2042.
34. Tschöpe C, Reinecke A, Seidl U, Yu M, Gavriluk V, Riester U, Gohlke P, Graf K Bader M, Hilgenfeldt U, Pesquero JB, Ritz E, Linger T. 1999. Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats. Am J Physiol 277:H2333-H2340.
35. VavrekR, Stewart JM. 1985. Competitive antagonists of bradykinin. Peptides 6:161-164.
36. Velarde V, Ullian ME, Morinelli TA, Mayfield RK, Jaffa AA. 1999. Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. Am J Physiol 277:C253-C261.
37. Velarde V, de la Cerda PM, Duarte C, Arancibia F, Abbott E, González A, Moreno F, Jaffa AA. 2004. Role of reactive oxygen species in bradykinin-induced proliferation of vascular smooth muscle cells. Biol Res 37:419-430.
38. Wang Y, Thakur A, Sun Y, Wu J, Biliran H, Bollig A, Liao DJ. 2007. Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells : Proteomic characterization. Exp Cell Res 313:357-368.
39. Xia CF, Yin H, Borlongan CV, Chao L, Chao J. 2004. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 43:452-459.
40. Yu H, Bowden DW, Spray BJ, Rich SS, Freedman BI. 1998. Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease. Hypertension 31:906-911.